-
1
-
-
33947610184
-
Health economic issues in Rheumatoid Arthritis
-
Kobelt G. Health economic issues in Rheumatoid Arthritis. Scand J Rheumatol 2006;35:415-25.
-
(2006)
Scand J Rheumatol
, vol.35
, pp. 415-425
-
-
Kobelt, G.1
-
2
-
-
18644386700
-
International variation in resource utilisation and treatment costs for rheumatoid arthritis. A systematic literature review
-
Rosery H, Bergemann R, Maxion-Bergemann S. International variation in resource utilisation and treatment costs for rheumatoid arthritis. A systematic literature review. Pharmacoeconomics 2005;23:243-57.
-
(2005)
Pharmacoeconomics
, vol.23
, pp. 243-257
-
-
Rosery, H.1
Bergemann, R.2
Maxion-Bergemann, S.3
-
3
-
-
33747759417
-
Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany
-
Huscher D, Merkesdal S, Thiele K, Zeidler H, Schneider M, Zink A, et al. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis 2006;65:1175-83.
-
(2006)
Ann Rheum Dis
, vol.65
, pp. 1175-1183
-
-
Huscher, D.1
Merkesdal, S.2
Thiele, K.3
Zeidler, H.4
Schneider, M.5
Zink, A.6
-
4
-
-
35648964844
-
-
Kobelt G, Richard B, Peeters P, Sany J. Costs and quality of life of patients with RA in France. ACR abstract 2006; Bone Joint Spine. In press.
-
Kobelt G, Richard B, Peeters P, Sany J. Costs and quality of life of patients with RA in France. ACR abstract 2006; Bone Joint Spine. In press.
-
-
-
-
5
-
-
0037385979
-
Economic evaluation of programs or interventions in the management of rheumatoid arthritis: Defining a reference case
-
for the OMERACT group
-
Maetzel A, Tugwell P, Boers M, for the OMERACT group. Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a reference case. J Rheumatol 2003;30:891-6.
-
(2003)
J Rheumatol
, vol.30
, pp. 891-896
-
-
Maetzel, A.1
Tugwell, P.2
Boers, M.3
-
6
-
-
0022633115
-
Measurement of health state utilities for economic appraisal. A review
-
Torrance G. Measurement of health state utilities for economic appraisal. A review. J Health Econ 1986;5:1-30.
-
(1986)
J Health Econ
, vol.5
, pp. 1-30
-
-
Torrance, G.1
-
9
-
-
0025688231
-
EuroQol: A new facility for the measurement of health-related quality of life
-
The EuroQol Group
-
The EuroQol Group. EuroQol: a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208.
-
(1990)
Health Policy
, vol.16
, pp. 199-208
-
-
-
10
-
-
0003473591
-
-
York: Centre for Health Economics, University of York
-
Dolan P, Gudex C, Kind P, Williams A. A social tariff for EuroQol: Results from a UK general population survey, Discussion Paper 138. York: Centre for Health Economics, University of York, 1995.
-
(1995)
A social tariff for EuroQol: Results from a UK general population survey, Discussion
-
-
Dolan, P.1
Gudex, C.2
Kind, P.3
Williams, A.4
-
12
-
-
0033003967
-
Economic consequences of the progression of rheumatoid arthritis in Sweden
-
Kobelt G, Eberhardt K, Jönsson L, Jönsson B. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum 1999;42:347-56.
-
(1999)
Arthritis Rheum
, vol.42
, pp. 347-356
-
-
Kobelt, G.1
Eberhardt, K.2
Jönsson, L.3
Jönsson, B.4
-
13
-
-
0031134856
-
Measuring health-related quality of life in rheumatoid arthritis: Validity, responsiveness and reliability of EuroQol (EQ-5D)
-
Hurst N, Kind P, Ruta D, Hunter M, Stubbings A. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol 1997;36:551-9.
-
(1997)
Br J Rheumatol
, vol.36
, pp. 551-559
-
-
Hurst, N.1
Kind, P.2
Ruta, D.3
Hunter, M.4
Stubbings, A.5
-
14
-
-
0036746102
-
Modelling the progression of rheumatoid arthritis, a two-country model to estimate costs and consequences of RA
-
Kobelt G, Jönsson L, Lindgren P, Young A, Eberhardt K. Modelling the progression of rheumatoid arthritis, a two-country model to estimate costs and consequences of RA. Arthritis Rheum 2002;46:2310-9.
-
(2002)
Arthritis Rheum
, vol.46
, pp. 2310-2319
-
-
Kobelt, G.1
Jönsson, L.2
Lindgren, P.3
Young, A.4
Eberhardt, K.5
-
15
-
-
24144476312
-
Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis
-
Kobelt G, Lindgren P, Lindroth Y, Jacobson L, Eberhardt K. Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis. Rheumatology (Oxford) 2005;44:1169- 75.
-
(2005)
Rheumatology (Oxford)
, vol.44
, pp. 1169-1175
-
-
Kobelt, G.1
Lindgren, P.2
Lindroth, Y.3
Jacobson, L.4
Eberhardt, K.5
-
16
-
-
0347950999
-
TNF-inhibitors in the treatment of rheumatoid arthritis in clinical practice: Costs and outcomes in a follow-up study of patients with RA treated with etanercept or infliximab in southern Sweden
-
Kobelt G, Eberhardt K, Geborek P. TNF-inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow-up study of patients with RA treated with etanercept or infliximab in southern Sweden. Ann Rheum Dis 2004;63:4-10.
-
(2004)
Ann Rheum Dis
, vol.63
, pp. 4-10
-
-
Kobelt, G.1
Eberhardt, K.2
Geborek, P.3
-
17
-
-
33646559212
-
-
Hulsemann JL, Ruof J, Zeidler H, Mittendorf T. Costs in rheumatology: results and lessons learned from the 'Hannover Costing Study'. Rheumatol Int 2005;26:704-11.
-
Hulsemann JL, Ruof J, Zeidler H, Mittendorf T. Costs in rheumatology: results and lessons learned from the 'Hannover Costing Study'. Rheumatol Int 2005;26:704-11.
-
-
-
-
18
-
-
25644440064
-
Analytic choices in economic models of treatments for rheumatoid arthritis: What makes a difference?
-
Drummond MF, Barbieri M, Wong JB. Analytic choices in economic models of treatments for rheumatoid arthritis: what makes a difference? Med Decis Making 2005;25:520-33.
-
(2005)
Med Decis Making
, vol.25
, pp. 520-533
-
-
Drummond, M.F.1
Barbieri, M.2
Wong, J.B.3
-
19
-
-
16344370052
-
An overview of economic evaluations for drugs used in rheumatoid arthritis: Focus on tumour necrosis factor-alpha antagonists
-
Bansback NJ, Regier DA, Ara R, Brennan A, Shojania K, Esdaile JM, et al. An overview of economic evaluations for drugs used in rheumatoid arthritis: focus on tumour necrosis factor-alpha antagonists. Drugs 2005;65:473-96.
-
(2005)
Drugs
, vol.65
, pp. 473-496
-
-
Bansback, N.J.1
Regier, D.A.2
Ara, R.3
Brennan, A.4
Shojania, K.5
Esdaile, J.M.6
-
22
-
-
0345294739
-
The cost-effectiveness of infliximab (Remicade(R)) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study
-
Kobelt G, Jönsson L, Young A, Eberhardt K. The cost-effectiveness of infliximab (Remicade(R)) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology 2003;42:326-35.
-
(2003)
Rheumatology
, vol.42
, pp. 326-335
-
-
Kobelt, G.1
Jönsson, L.2
Young, A.3
Eberhardt, K.4
-
23
-
-
0036800337
-
Estimating the cost-effectiveness of infliximab for rheumatoid arthritis
-
Wong J, Singh G, Kavanough A. Estimating the cost-effectiveness of infliximab for rheumatoid arthritis. Am J Med 2002;113:400-8.
-
(2002)
Am J Med
, vol.113
, pp. 400-408
-
-
Wong, J.1
Singh, G.2
Kavanough, A.3
-
24
-
-
17344389740
-
The use of modelling to evaluate new drugs for patients with chronic conditions: The case of antibodies against tumour necrosis factor in rheumatoid arthritis
-
Barton P, Jobanputra P, Wilson J, Bryan S, Burls A. The use of modelling to evaluate new drugs for patients with chronic conditions: the case of antibodies against tumour necrosis factor in rheumatoid arthritis. Health Technology Assessment 2004;8:1-91.
-
(2004)
Health Technology Assessment
, vol.8
, pp. 1-91
-
-
Barton, P.1
Jobanputra, P.2
Wilson, J.3
Bryan, S.4
Burls, A.5
-
25
-
-
0345832266
-
Modeling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK
-
Brennan A, Bansback N, Reynolds A, Conway P. Modeling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology 2004;43:62-72.
-
(2004)
Rheumatology
, vol.43
, pp. 62-72
-
-
Brennan, A.1
Bansback, N.2
Reynolds, A.3
Conway, P.4
-
26
-
-
21344455325
-
Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden
-
Bansback NJ, Brennan A, Ghatnekar O. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. Ann Rheum Dis 2005;64:995-1002.
-
(2005)
Ann Rheum Dis
, vol.64
, pp. 995-1002
-
-
Bansback, N.J.1
Brennan, A.2
Ghatnekar, O.3
-
27
-
-
23444460855
-
Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial
-
Kobelt G, Lindgren P, Singh A, Klareskog L. Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial. Ann Rheum Dis 2005;64:1174-9.
-
(2005)
Ann Rheum Dis
, vol.64
, pp. 1174-1179
-
-
Kobelt, G.1
Lindgren, P.2
Singh, A.3
Klareskog, L.4
-
28
-
-
34547839821
-
Modelling the cost effectiveness of TNF-{alpha} antagonists in the management of rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Registry
-
Brennan A, Bansback N, Nixon R, Madan J, Harrison M, Watson K, et al. Modelling the cost effectiveness of TNF-{alpha} antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry. Rheumatology (Oxford) 2007;46:1345-54.
-
(2007)
Rheumatology (Oxford)
, vol.46
, pp. 1345-1354
-
-
Brennan, A.1
Bansback, N.2
Nixon, R.3
Madan, J.4
Harrison, M.5
Watson, K.6
|